MLL Rearranged
KMT2A (MLL) rearrangements in acute leukemias. Targeted by emerging menin inhibitors (revumenib, ziftomenib).
No Clinical Trials found for this biomarker.
KMT2A (MLL) rearrangements in acute leukemias. Targeted by emerging menin inhibitors (revumenib, ziftomenib).
No Clinical Trials found for this biomarker.